Ebglyss® (lebrikizumab-lbkz)
for Atopic Dermatitis – Eczema

Ebglyss (lebrikizumab) is a biologic treatment for moderate-to-severe atopic dermatitis in patients 12 years and older who have not responded to topical treatments. Ebglyss is an interleukin-13 antagonist that works by blocking IL-13 to improve eczema symptoms. It targets IL-13, a key protein involved in eczema-related inflammation, helping to reduce itch, dryness, and skin irritation.

Heart
Medication Guide Icon Medication Guide
TV Commercial Icon TV Commercial
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Atopic Dermatitis - Eczema